These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 20964609

  • 1. Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics.
    Chen CP, Haas-Kogan D.
    Expert Rev Mol Diagn; 2010 Oct; 10(7):883-95. PubMed ID: 20964609
    [Abstract] [Full Text] [Related]

  • 2. The use of imaging in the diagnosis and staging of hepatobiliary malignancies.
    Miller G, Schwartz LH, D'Angelica M.
    Surg Oncol Clin N Am; 2007 Apr; 16(2):343-68. PubMed ID: 17560517
    [Abstract] [Full Text] [Related]

  • 3. Surgical and nonsurgical management of primary and metastatic liver tumors.
    Zibari GB, Riche A, Zizzi HC, McMillan RW, Aultman DF, Boykin KN, Gonzalez E, Nandy I, Dies DF, Gholson CF, Holcombe RF, McDonald JC.
    Am Surg; 1998 Mar; 64(3):211-20; discussion 220-1. PubMed ID: 9520809
    [Abstract] [Full Text] [Related]

  • 4. [Ultra-rapid magnetic resonance tomography: a quantum leap in preoperative hepatobiliary diagnosis?].
    Hagmüller E, Sturm J, Gaa J, Georgi M.
    Langenbecks Arch Chir Suppl Kongressbd; 1997 Mar; 114():431-3. PubMed ID: 9574173
    [Abstract] [Full Text] [Related]

  • 5. Cytoplasmic staining of TTF-1 in the differential diagnosis of hepatocellular carcinoma vs cholangiocarcinoma and metastatic carcinoma of the liver.
    Lei JY, Bourne PA, diSant'Agnese PA, Huang J.
    Am J Clin Pathol; 2006 Apr; 125(4):519-25. PubMed ID: 16627262
    [Abstract] [Full Text] [Related]

  • 6. Management of combined hepatocellular and cholangiocarcinoma.
    Kassahun WT, Hauss J.
    Int J Clin Pract; 2008 Aug; 62(8):1271-8. PubMed ID: 18284443
    [Abstract] [Full Text] [Related]

  • 7. Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers.
    Gowda GA.
    Biomark Med; 2010 Apr; 4(2):299-314. PubMed ID: 20406071
    [Abstract] [Full Text] [Related]

  • 8. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
    Torzilli G, Makuuchi M, Ferrero A, Takayama T, Hui AM, Abe H, Inoue K, Nakahara K.
    Hepatogastroenterology; 2002 Apr; 49(45):740-5. PubMed ID: 12063982
    [Abstract] [Full Text] [Related]

  • 9. High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms.
    Abe N, Watanabe T, Izumisato Y, Suzuki Y, Masaki T, Mori T, Sugiyama M, Fusco A, Atomi Y.
    J Gastroenterol; 2003 Apr; 38(12):1144-9. PubMed ID: 14714251
    [Abstract] [Full Text] [Related]

  • 10. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study.
    Bergquist A, Glaumann H, Persson B, Broomé U.
    Hepatology; 1998 Feb; 27(2):311-6. PubMed ID: 9462625
    [Abstract] [Full Text] [Related]

  • 11. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma.
    Jeon TY, Kim SH, Lee WJ, Lim HK.
    Abdom Imaging; 2010 Jun; 35(3):337-45. PubMed ID: 19350315
    [Abstract] [Full Text] [Related]

  • 12. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
    Shiran MS, Isa MR, Sherina MS, Rampal L, Hairuszah I, Sabariah AR.
    Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
    [Abstract] [Full Text] [Related]

  • 13. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
    Garioud A, Seksik P, Chrétien Y, Corphechot C, Poupon R, Poupon RE, Chazouillères O.
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
    [Abstract] [Full Text] [Related]

  • 14. The Das-1 immunostain is useful for discriminating metastatic colon adenocarcinoma from cholangiocarcinoma and hepatocellular carcinoma.
    Zimmerman RL, Das KM, Fogt F, Burke M, Murakata LA.
    Oncol Rep; 2002 Jul; 9(6):1369-72. PubMed ID: 12375050
    [Abstract] [Full Text] [Related]

  • 15. [Value of diagnostic laparoscopy in primary malignant liver tumors].
    Wolff M, Ulrich A, Müller A, Hirner A.
    Langenbecks Arch Chir Suppl Kongressbd; 1998 Jul; 115():1331-4. PubMed ID: 9931873
    [Abstract] [Full Text] [Related]

  • 16. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
    Dong H, Cong WL, Zhu ZZ, Wang B, Xian ZH, Yu H.
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
    [Abstract] [Full Text] [Related]

  • 17. New frontiers in biomarkers for hepatocellular carcinoma.
    Giannelli G, Antonaci S.
    Dig Liver Dis; 2006 Nov; 38(11):854-9. PubMed ID: 16782417
    [Abstract] [Full Text] [Related]

  • 18. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches.
    Breuhahn K, Gores G, Schirmacher P.
    Hepatology; 2011 Jun; 53(6):2112-21. PubMed ID: 21433041
    [Abstract] [Full Text] [Related]

  • 19. Genetic profiling of human hepatocellular carcinoma.
    Lee JS, Thorgeirsson SS.
    Semin Liver Dis; 2005 Jun; 25(2):125-32. PubMed ID: 15918141
    [Abstract] [Full Text] [Related]

  • 20. Hepatobiliary tumours.
    Simcock R.
    Practitioner; 2001 Aug; 245(1625):668-74. PubMed ID: 11524939
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.